NCT02949531

Brief Summary

Oxygen is routinely given to patients with common conditions such as COPD and heart failure. There is no evidence behind giving oxygen to patients specifically in heart failure due to a stiff heart. This study aims to explore the effect oxygen has on the ability of patients with chronic heart failure and the ability to exercise. Other common variables will be assessed such as heart rate and blood pressure to observe the response to varying concentrations of oxygen. The concentrations chosen are commonly offered in hospitals and indeed are being delivered through standard equipment found in all hospitals in the country. It is hoped that studying the effect of short term oxygen on patients with heart failure will help to identify the effectiveness of oxygen in longer term therapy for patients who are often breathless with a decreased exercise tolerance.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for phase_2 heart-failure

Timeline
Completed

Started Nov 2016

Shorter than P25 for phase_2 heart-failure

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 3, 2016

Completed
28 days until next milestone

First Posted

Study publicly available on registry

October 31, 2016

Completed
3 days until next milestone

Study Start

First participant enrolled

November 3, 2016

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 15, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 15, 2017

Completed
Last Updated

June 26, 2019

Status Verified

September 1, 2016

Enrollment Period

3 months

First QC Date

October 3, 2016

Last Update Submit

June 24, 2019

Conditions

Outcome Measures

Primary Outcomes (1)

  • change in exercise time with the use of 21%, 28% and 40% oxygen

    the total time cycled in each arm

    at 3 weeks

Secondary Outcomes (2)

  • change in shortness of breath with the use of 21%, 28% and 40% oxygen

    at 3 weeks

  • change in Peak metabolic equivalent with the use of 21%, 28% and 40% oxygen

    at 3 weeks

Study Arms (3)

21% oxygen

ACTIVE COMPARATOR

room air will be delivered via Venturi mask during cycle ergometry

Drug: oxygen

28% oxygen

ACTIVE COMPARATOR

28% oxygen will be delivered via Venturi mask during cycle ergometry

Drug: oxygen

40% oxygen

ACTIVE COMPARATOR

40% oxygen will be delivered via Venturi mask during cycle ergometry

Drug: oxygen

Interventions

oxygenDRUG
21% oxygen28% oxygen40% oxygen

Eligibility Criteria

Age50 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Over 50 years of age and able and willing to give consent
  • Have signs and/or symptoms of heart failure
  • Left ventricular ejection fraction \> 45%
  • NT-pro BNP \> 220 pg/ml (in the previous 12 months)
  • On any diuretic

You may not qualify if:

  • Unable or unwilling to give consent
  • Recent (\<1 month) acute myocardial infarct or cerebrovascular event
  • Significant renal dysfunction (eGFR \<30 ml.min-1.1.73m-2)
  • Significant anaemia (Haemoglobin \< 100 g.L-1)
  • Systolic blood pressure \<90 mmHg, or \>180 mmHg
  • Severe mitral or aortic valve disease
  • Diagnosis of severe chronic lung disease
  • Involvement in another medicinal trial within the past four weeks
  • Unable to use cycle
  • Any planned admission in the following 3-4 weeks (patient can be reconsidered for enrolment after planned admission)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Shah P, Pellicori P, Rimmer S, Rigby AS, Clark AL. Effect of increased inspired oxygen on exercise performance in patients with heart failure and normal ejection fraction. Int J Cardiol. 2018 Oct 1;268:166-169. doi: 10.1016/j.ijcard.2018.05.029. Epub 2018 May 24.

    PMID: 29803343BACKGROUND

MeSH Terms

Conditions

Heart Failure

Interventions

Oxygen

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular Diseases

Intervention Hierarchy (Ancestors)

ChalcogensElementsInorganic ChemicalsGases

Study Officials

  • Andrew Clark

    Castle Hill Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER GOV
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 3, 2016

First Posted

October 31, 2016

Study Start

November 3, 2016

Primary Completion

February 15, 2017

Study Completion

February 15, 2017

Last Updated

June 26, 2019

Record last verified: 2016-09

Data Sharing

IPD Sharing
Will not share